RSV disease burden and nirsevimab effectiveness in young children from 2023-2024
About The Study: This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal RSV vaccine uptake was low, but nirsevimab was effective against RSV-associated hospitalization. There is a potential for substantial public health impact with increased and equitable prevention product coverage in future seasons. Corresponding Author: To contact the corresponding author, Heidi L. Moline, MD, MPH, email ick6@cdc.gov. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamapediatrics.2024.5572) Editor’s ...
Read the release









